Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Dose-escalation of Flonoltinib Maleate Tablets in Patients With Bone Marrow Proliferative Tumors

NCT05115344 is registered in ClinicalTrials.gov with Guizhou Bailing Group Pharmaceutical Co Ltd as lead sponsor.

NCT NCT05115344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05115344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Dose-escalation of Flonoltinib Maleate Tablets in Patients With Bone Marrow Proliferative Tumors
Lead sponsor
Guizhou Bailing Group Pharmaceutical Co Ltd
Phase
Phase 1
Overall status
Withdrawn
Start date
November 12, 2021
Completion date
February 28, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis，mf, myeloproliferative neoplasm (mpn)